Alan D. Smith

3.1k total citations
35 papers, 635 citations indexed

About

Alan D. Smith is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Alan D. Smith has authored 35 papers receiving a total of 635 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Alan D. Smith's work include Renal cell carcinoma treatment (9 papers), Prostate Cancer Treatment and Research (9 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Alan D. Smith is often cited by papers focused on Renal cell carcinoma treatment (9 papers), Prostate Cancer Treatment and Research (9 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Alan D. Smith collaborates with scholars based in United Kingdom, United States and Spain. Alan D. Smith's co-authors include Timothy A. Yap, Johann S. de Bono, Roberta Ferraldeschi, Desam Roda, Joaquı́n Mateo, Bissan Al‐Lazikani, Paul Workman, Zafeiris Zafeiriou, David Lorente and Robert J. Motzer and has published in prestigious journals such as Journal of Clinical Oncology, Circulation Research and Nature Reviews Drug Discovery.

In The Last Decade

Alan D. Smith

32 papers receiving 618 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan D. Smith United Kingdom 14 361 236 234 171 68 35 635
Carlo Cattrini Italy 15 464 1.3× 297 1.3× 203 0.9× 194 1.1× 85 1.3× 40 703
Anis Hamid United States 13 425 1.2× 206 0.9× 166 0.7× 182 1.1× 94 1.4× 54 599
Jaymes Holland United States 14 299 0.8× 259 1.1× 294 1.3× 143 0.8× 43 0.6× 25 769
Carolyn Evan United States 10 387 1.1× 187 0.8× 140 0.6× 168 1.0× 78 1.1× 20 527
Maria Rosa Cappelletti Italy 13 251 0.7× 312 1.3× 213 0.9× 239 1.4× 57 0.8× 32 635
Yusuke Imamura Japan 15 399 1.1× 154 0.7× 315 1.3× 169 1.0× 61 0.9× 77 765
Sven Gogov Switzerland 12 409 1.1× 351 1.5× 294 1.3× 145 0.8× 43 0.6× 25 804
Marcelo V. Negrão United States 15 449 1.2× 491 2.1× 223 1.0× 128 0.7× 61 0.9× 65 769
Ione Tamagnini Italy 13 249 0.7× 325 1.4× 269 1.1× 141 0.8× 51 0.8× 24 720
Toshiaki Shinojima Japan 15 290 0.8× 196 0.8× 273 1.2× 180 1.1× 32 0.5× 46 664

Countries citing papers authored by Alan D. Smith

Since Specialization
Citations

This map shows the geographic impact of Alan D. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan D. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan D. Smith more than expected).

Fields of papers citing papers by Alan D. Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan D. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan D. Smith. The network helps show where Alan D. Smith may publish in the future.

Co-authorship network of co-authors of Alan D. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Alan D. Smith. A scholar is included among the top collaborators of Alan D. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan D. Smith. Alan D. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pal, Sumanta K., Javier Puente, Daniel Yick Chin Heng, et al.. (2022). Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. European Urology. 82(3). 283–292. 17 indexed citations
3.
Lee, Chung‐Han, Yin Wan, Alan D. Smith, Ran Xie, & Robert J. Motzer. (2021). Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. European Urology Open Science. 31. 1–9. 2 indexed citations
4.
5.
Jiang, Di, Nazanin Fallah‐Rad, Roy Lee, et al.. (2020). Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer. European Urology. 79(2). 177–179. 4 indexed citations
6.
Grünwald, Viktor, Thomas Powles, Toni K. Choueiri, et al.. (2019). Lenvatinib Plus Everolimus or Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Study Design and Rationale. Future Oncology. 15(9). 929–941. 38 indexed citations
7.
Makker, Vicky, Antonio Casado, Carol Aghajanian, et al.. (2019). A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.. Journal of Clinical Oncology. 37(15_suppl). TPS5607–TPS5607. 10 indexed citations
8.
Smith, Alan D., Matthew Truong, Robert G. Bristow, et al.. (2016). The Utility of Serum CA9 for Prognostication in Prostate Cancer. Anticancer Research. 36(9). 4489–4492. 11 indexed citations
9.
Rescigno, Pasquale, David Lorente, Diletta Bianchini, et al.. (2016). Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology. 70(5). 724–731. 52 indexed citations
10.
Yap, Timothy A., Alan D. Smith, Roberta Ferraldeschi, et al.. (2016). Drug discovery in advanced prostate cancer: translating biology into therapy. Nature Reviews Drug Discovery. 15(10). 699–718. 112 indexed citations
11.
Lorente, David, Joaquı́n Mateo, Zafeiris Zafeiriou, et al.. (2015). Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nature Reviews Urology. 12(1). 37–47. 58 indexed citations
12.
13.
Smith, Alan D., Desam Roda, & Timothy A. Yap. (2014). Strategies for modern biomarker and drug development in oncology. Journal of Hematology & Oncology. 7(1). 70–70. 89 indexed citations
14.
Mateo, Joaquı́n, Alan D. Smith, Michael Ong, & Johann S. de Bono. (2014). Novel drugs targeting the androgen receptor pathway in prostate cancer. Cancer and Metastasis Reviews. 33(2-3). 567–579. 23 indexed citations
15.
Ravi, Praful, Joaquı́n Mateo, David Lorente, et al.. (2014). External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone. European Urology. 66(1). 8–11. 20 indexed citations
16.
Banerji, Udai, Alan D. Smith, Andrea Zivi, et al.. (2014). Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719.. Journal of Clinical Oncology. 32(15_suppl). e13559–e13559. 3 indexed citations
17.
Smith, Alan D., Kelvin Chan, Howard J. Lim, & Winson Y. Cheung. (2012). A multicenter analysis of prognostic factors in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib.. Journal of Clinical Oncology. 30(15_suppl). e14532–e14532. 1 indexed citations
18.
Conroy, Carol, Christina Stanley, A. Brent Eastman, et al.. (2008). Asphyxia. American Journal of Forensic Medicine & Pathology. 29(1). 14–18. 13 indexed citations
19.
Smith, Alan D.. (1997). Survey of locked facilities in Scottish psychiatric hospitals. Psychiatric Bulletin. 21(2). 77–79. 11 indexed citations
20.
Smith, Alan D.. (1997). Databases and research on mentally abnormal offenders. Journal of Forensic Psychiatry. 8(2). 370–389. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carlo Cattrini Breakdown of academic impact, for papers by Anis Hamid Breakdown of academic impact, for papers by Jaymes Holland Breakdown of academic impact, for papers by Carolyn Evan Breakdown of academic impact, for papers by Maria Rosa Cappelletti Breakdown of academic impact, for papers by Yusuke Imamura Breakdown of academic impact, for papers by Sven Gogov Breakdown of academic impact, for papers by Marcelo V. Negrão Breakdown of academic impact, for papers by Ione Tamagnini Breakdown of academic impact, for papers by Toshiaki Shinojima
Rankless by CCL
2026